BANCO BBVA Argentina SA ADRS (BBAR): $BBAR: Now 4.80............. Argentina s...

$BBAR: Now 4.80............. Argentina stiillllllllllllll HOT !!!!!!!!!!

makinezmoney · 2023-01-17T16:10:11.7830000Z

$BBAR: Now 4.80............. Argentina stiillllllllllllll HOT !!!!!!!!!! https://slm-assets.secondlife.com/assets/15100381/lightbox/argentina-bikini.jpg?1474369773 GO $BBAR

Play Episode

3min

Proactive - Interviews for investors

Firefly Metals hits high-grade copper-gold at Green Bay

Firefly Metals Ltd managing director Steve Parsons talked with Proactive about the company’s latest drill results from the Green Bay Copper-Gold Project. Parsons highlighted a series of significant intercepts from ongoing infill drilling, including a standout result of 14.2 metres at 7.5% copper equivalent. These results are part of an effort to upgrade the current 24.4 million-ton resource into the indicated category, which is essential for progressing the company’s engineering studies and maintaining ASX compliance. “In some of those infill zones, we’re seeing 50 metres or more at over 2% copper with gold,” Parsons said, underlining the robust nature of the mineralised system. Firefly currently has five underground rigs active, with three focused on infill drilling and two on step-out drilling aimed at further growing the resource. The company expects new results in the coming weeks and is also preparing to commence regional exploration drilling within a ten-kilometre radius of the planned processing plant. Parsons noted the geological potential of the area, stating that VMS high-grade copper-gold systems “typically find more than one,” expressing optimism about upcoming exploration. To stay updated on Firefly Metals Ltd and other mining developments, visit Proactive's YouTube channel. Don’t forget to like this video, subscribe, and turn on notifications for future updates. #Copper #Gold #FireflyMetals #GreenBayProject #MiningNews #DrillResults #VMSDeposits #ASX #CopperExploration #ResourceUpdate #ProactiveInvestors

Proactive - Interviews for investors

AI translation tech: Straker CEO talks IBM partnership

Straker Ltd CEO Grant Straker talked with Proactive at AIM"S Small and Midcap Conference about how the company is leveraging artificial intelligence to reshape the global language services industry. Straker explained how the business evolved from early content management systems into a leading AI-powered translation platform over the last 15 years. The company focuses on blending machine learning with human expertise to deliver high-quality, cost-effective language services. A key milestone has been the integration of its platform by IBM, which now uses Straker’s technology for all its internal translations. “They’ve gone from a multi-vendor traditional model to just us,” Straker said, highlighting how the move has streamlined IBM’s operations while reducing costs. He also discussed the company's proprietary "Terry" language model and its innovative quality estimation* system. This tool evaluates translated content for accuracy, determining whether it needs human review—improving efficiency and boosting gross margins. Straker outlined a clear investor case, emphasizing three pillars: financial strength, innovation, and global distribution. The company is targeting revenues of AUD 45 million for the year, with no debt, AUD 12 million in cash, and annual R&D investment of AUD 7 million. With operations in ten countries and strategic alignment with IBM’s AI stack, Straker positioned the company as well-placed to scale quickly through operating leverage in AI. #AI #StrakerLtd #GrantStraker #LanguageTech #TranslationAI #IBMPartnership #ArtificialIntelligence #InvestorUpdate #MachineTranslation #TechStocks #ASXStocks #TerryModel #QualityEstimation #ProactiveInvestors #SmallCapASX

Proactive - Interviews for investors

Actinogen targets $20B Alzheimer’s market with Xanamem

Actinogen Medical Ltd Managing Director and CEO Dr Stephen Gourlay talked with Proactive at the AIM's Small and Midcap conference about the company’s lead asset, Xanamem, and its development in Alzheimer’s disease and depression. Dr Gourlay explained that Xanamem is an oral, once-a-day drug designed to modulate cortisol levels in the brain without interfering with the body’s essential stress response. “We’ve also shown some positive data, you know, phase two and depression as well, which is very exciting because that validates its mechanism,” he said. He outlined the commercial opportunity in both Alzheimer’s and depression. While depression is more prevalent, the Alzheimer's market offers larger potential revenue. He noted that current treatments either have side effects or provide only temporary cognitive improvement, whereas Xanamem could modify the disease course with a better safety profile. Dr Gourlay discussed Actinogen’s recent momentum, including positive results in a depression trial, a number of peer-reviewed publications, and the upcoming interim analysis from its Alzheimer’s trial in Australia and the US. He said, “The upside from a positive Alzheimer’s trial is completely massive… a multi-billion dollar asset.” The company is currently trading below the total investment into drug development, which Dr Gourlay described as a compelling investment case. #Actinogen #Xanamem #AlzheimersResearch #DepressionTreatment #BiotechStocks #ClinicalTrials #Neuroscience #PharmaInnovation #ASX #ProactiveInvestors

Proactive - Interviews for investors

atai CEO outlines strategic focus for 2025 including four major data readouts

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) CEO and co-founder Dr Srinivas Rao talked with Proactive about the company's upcoming clinical milestones and strategic focus in 2025. Rao outlined four major clinical readouts across atai’s pipeline of short-duration psychedelics, including updates on VLS-01, BPL-003, RL-007 and EMP-01. The company has dosed its first patient in the VLS-01 trial for treatment-resistant depression, a study that includes an innovative two-dose approach. Rao noted, “This will be the first data set that's going to come out that really addresses the question of what is the incremental benefit of a re-dose?” The trial is expected to read out in Q1 of next year. The BPL-003 trial has completed enrolment and is expected to report results mid-year, alongside RL-007, which targets cognitive impairment associated with schizophrenia. EMP-01, which focuses on social anxiety disorder, is also underway with data expected around the same time as VLS-01. Rao also highlighted that atai recently raised additional capital, extending its funding runway into 2027. The company is focused on short-duration psychedelics with easy-to-administer formulations, such as VLS-01's oral strip delivery system. For more interviews and updates from innovative biotech companies, visit Proactive’s YouTube channel. Don’t forget to like the video, subscribe to the channel, and turn on notifications for future content. #ataiLifeSciences #Biotech #Pharmaceuticals #PsychedelicTherapy #ClinicalTrials #MentalHealth #TreatmentResistantDepression #Schizophrenia #SocialAnxietyDisorder #VLS01 #RL007 #BPL003 #EMP01 #ProactiveInvestors

Followers	1347
Posts	27785
Boards Moderated	51
Alias Born	12/10/2012

Volume:	4
Day Range:
Bid:
Ask:
Last Trade Time:	4:08:20 AM EDT
Total Trades:	4

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

BBAR Detailed Quote

Recent BBAR News

More BBAR News

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Recent BBAR News

Go Ad-Free